

CLAIMS

mbx

5 1. A method of treating hypertension in a mammal, which has experienced intrauterine under nutrition and/or growth retardation or an adverse post-natal environment, the method comprising the step of administering to the mammal an effective amount of an agent, wherein the agent is a ligand which binds to, and activates, the growth hormone receptor.

10 2. A method of treating hypertension in a mammal, which has experienced intrauterine under nutrition and/or growth retardation or an adverse post-natal environment, the method comprising the step of administering to the mammal an effective amount of an agent selected from the group consisting of growth hormone, an analog thereof, and a functionally equivalent ligand.

15
Sue
aa1

3. A method as claimed in either claim 1 or claim 2 wherein the mammal has experienced an adverse postnatal environment comprising a hypocaloric or hypercaloric diet.

20 4. A method as claimed in any one of claims 1 to 3 wherein the mammal is an adult mammal.

5. A method as claimed claim 4 wherein the mammal is an adult human.

25 6. A method as claimed in claim 5 wherein the agent administered to the mammal is growth hormone.

30
Sue
aa2

7. A method as claimed in any one of the preceding claims wherein the agent is administered to the mammal in combination with a second anti-hypertensive agent.

8. A method of treating hypertension in a mammal, which has experienced intrauterine under nutrition and/or growth retardation or an adverse post-natal environment, the method comprising the step of increasing the effective concentration of growth hormone, an analog thereof or a functionally equivalent ligand in the mammal.

9. A method as claimed in claim 8 wherein the mammal has experienced an adverse postnatal environment comprising a hypocaloric or hypercaloric diet.

10. A method as claimed in either claim 8 or claim 9 wherein the effective concentration of the growth hormone, an analog thereof or a functionally equivalent ligand is increased through administration of an agent which either stimulates production of growth hormone or which lessens or prevents inhibition of growth hormone activity.

11. A method as claimed in either claim 8 or claim 9 wherein the effective concentration of growth hormone is increased through direct administration of growth hormone.

12. A method as claimed in any one of claims 8 to 11 wherein the mammal is an adult human.

13. The use, in the preparation of a medicament for treating hypertension in a mammal, which has experienced intrauterine under nutrition and/or growth retardation or an adverse post-natal environment, of an agent selected from the group consisting of growth hormone, an analog thereof and a functionally equivalent ligand.

14. The use as claimed in claim 13 wherein the mammal has experienced an adverse postnatal environment comprising a hypocaloric or hypercaloric diet.

5 15. The use as claimed in either claim 13 or claim 14 wherein the medicament is for treating an adult human.

10 16. The use as claimed in any one of claims 13 to 15 wherein the agent is growth hormone.

17. The use as claimed in any one of claims 13 to 16 wherein the medicament is for administration in combination with a second anti-hypertensive agent.

15 18. The use, in the preparation of a medicament for treating hypertension in a mammal, which has experienced intrauterine under nutrition and/or growth retardation or an adverse post-natal environment, of an agent which either stimulates production of growth hormone or which lessens or prevents inhibition of growth hormone activity.

20 19. The use as claimed in claim 18 wherein the mammal is an adult human.

25

CSPEC02341

0955704-071001
T08T20-10295860